

3. Providing technical expertise and/or financial support for (e.g. facilities, personnel and expertise) for CRADA-related Government activities.

4. Accomplishing objectives according to an appropriate timetable to be outlined in the CRADA Collaborator's proposal.

5. The willingness to commit best effort and demonstrated resources to the research, development and commercialization of this technology.

6. The demonstration of expertise in the commercial development, production, marketing and sales of products related to this area of technology.

8. The willingness to cooperate with the National Cancer Institute in the timely publication of research results.

9. The agreement to be bound by the appropriate DHHS regulating to human subjects, and all PHS policies relating to the use and care of laboratory animals.

10. The willingness to accept the legal provisions and language of the CRADA with only minor modifications, if any. These provisions govern the equitable distribution of patent rights to CRADA inventions.

Dated: April 26, 1998.

Kathleen Sybert,

Acting Director, Technology Development & Commercialization Branch, National Cancer Institute, National Institutes of Health.

[FR Doc. 98-12110 Filed 5-6-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging: Opportunity for a Cooperative Research and Development Agreement (CRADA) To Develop a Vaccine for Pneumonia

AGENCY: National Institutes of Health (NIH), PHS, DHHS/NIH, NIH, PHS, DHHS.

ACTION: Notice.

SUMMARY: The National Institute on Aging (NIA) is seeking a Collaborator to participate in a Cooperative Research and Development Agreement (CRADA) to develop a vaccine for pneumonia. The term of the CRADA will be up to five (5) years.

ADDRESSES: Inquiries and proposals regarding this opportunity should be addressed to Bruce D. Goldstein, J.D., Technology Development and Commercialization Branch, National Cancer Institute, 6120 Executive Blvd., EPS Suite 450, Rockville, Maryland

20852, telephone number 301-496-0477, FAX number 301-402-2117.

DATES: interested parties are advised to notify this office in writing of their intent to file a formal proposal no later than FIFTEEN (15) days from the date of this advertisement. Formal proposals must be submitted to this office no later than TWENTY (20) days from the date of this notice.

SUPPLEMENTARY INFORMATION: A CRADA is the anticipated joint agreement to be entered into by NIA pursuant to the Federal Technology Transfer Act of 1986, as amended by the National Technology Transfer Act (Pub. L. 104-113 (Mar. 7, 1996)) and by Executive Order 12591 of April 10, 1987. The NCI owns U.S. Patent No. 4,455,032, concerning the use of phosphocholine hapten conjugates in vaccines, which presently is not licensed. NIA is now planning to develop a vaccine for pneumonia utilizing the invention in the NCI patent.

Under the present proposal, the specific goals of the CRADA will be the development of the following technology:

- Development of one or more vaccines utilizing the phosphocholine-hapten technology;
- and preclinical evaluation of the candidate vaccines.

Party Contributions

The role in NIA includes the following:

- (1) Develop, in cooperation with the Collaborator, candidate pneumonia vaccines;
- (2) Conduct preclinical trials of candidate vaccines in small mammal models;
- (3) Provide staff, expertise, & materials for the development and testing of promising vaccines, and provide work space and equipment for testing of the prototype vaccines; and
- (4) Jointly evaluate and publish the data generated with Collaborator.

The role of the successful Collaborator will include the following:

- (1) Provide an adequate supply of at least one mutually agreeable, GMP-grade carrier system, and provide expertise and assistance in the development and use of its vaccine carrier system(s);
- (2) Provide resources, staff, expertise, and funding, as necessary, in support of the research goals; and
- (3) Develop and market any promising vaccines.

Selection Criteria

Proposals submitted for consideration should fully address each of the following qualifications:

- (1) Expertise:
 - A. Demonstrated expertise in developing and producing high quality pharmaceutical compositions;
 - B. Demonstrated ability to secure national and/or international marketing and distribution of pharmaceutical compositions;
 - C. Demonstrated intellectual ability to guide development of product line which addresses the requirements of NIA;
- (2) Reputation: The successful Collaborator must be recognized in the pharmaceutical industry for:
 - A. Producing quality pharmaceutical products;
 - B. Indications of satisfaction by industry experts with the Collaborator's products; and
 - C. Commitment to the research and development of new pharmaceuticals.
- (3) Physical Resources:
 - A. An established headquarters with offices, space, and equipment;
 - B. Access to the organization during business hours by telephone, mail, e-mail, the Internet, and other evolving technologies; and
 - C. Sufficient financial resources to support, at a minimum, the current activities of the CRADA to meet the needs of NIA.

Dated: April 26, 1998.

Kathleen Sybert,

Acting Director, Technology Development & Commercialization Branch, National Cancer Institute, National Institutes of Health.

[FR Doc. 98-12109 Filed 5-6-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Center for Scientific Review Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Microbiological and Immunological Sciences.

Date: May 12, 1998.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4182, Telephone Conference.

Contact Person: Dr. William Branche, Scientific Review Administrator, 6701 Rockledge Drive, Room 4182, Bethesda, Maryland 20892, (301) 435-1148.

Name of SEP: Clinical Sciences.

Date: May 13, 1998.